As has been pointed out this isnt right but also, my initial response to a cortisol inhibitor backs up the problem with this trial- lowering cortisol benefits EVERYONE so how did they determine outlier effects for Alzheimer patients? They may have, but they didn't provide any detail on the trial and this is another fault with our ASX. They need to tighten their disclosure procedures for biomeds because we cant make informed decision-- merely gamble.
